Anna von Rossum is a Senior Scientist specializing in Multispecific Antibody Therapeutics at Zymeworks Inc., where responsibilities include advancing antibody therapeutics with a focus on multispecifics, cell-engagers, and checkpoint inhibitors since March 2019. Prior experience includes an Associate Scientist role at The Centre for Drug Research & Development, where Anna led immunological assays in various collaborations, and a Post-Doctoral Fellowship in Immunotherapy, contributing to CAR-based immunotherapies and intellectual property development. Anna earned a PhD in Transplant Immunology from Simon Fraser University, studying T cell death in solid organ transplantation, and holds a Bachelor's Degree in Microbiology and Immunology from the University of Victoria. Additional education includes completion of the HMX Pro Pharmacology program at Harvard Medical School.
This person is not in the org chart